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Background: Cognitive decline and Alzheimer’s disease often affect older adults with Down 
syndrome (DS) much earlier than those in the general population. There is also growing evi-
dence of the effects of negative life events on the mental health and behavior of individuals with 
intellectual disability. However, to our knowledge, this is the first study investigating objective 
cognitive decline following bereavement in aging individuals with DS.
Objective: The objective of this study was to determine whether cognitive decline correlates 
with bereavement following the recent loss of a caregiver or with behavioral changes in a sample 
of adult individuals with DS who do not meet the criteria for dementia or depression, using the 
longitudinal assessment of the Cambridge Cognitive Examination (CAMCOG), together with 
the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE).
Methods: We evaluated 18 subjects at baseline and over a follow-up period of 14–22 months, 
attempting to determine whether cognitive decline correlates with bereavement following the 
recent loss of the main caregiver or with behavioral changes (as assessed with the Neuropsy-
chiatric Inventory).
Results: The mean rate of change in CAMCOG was −1.83 (standard deviation 4.51). Behavioral 
changes had a significant direct influence on cognitive decline. When bereavement was accom-
panied by behavioral changes, the probability of cognitive decline was 87% (odds ratio 3.82). 
Conclusion: The occurrence of behavioral changes attributed to bereavement following the loss 
of the primary caregiver significantly increases the probability of cognitive decline in individuals 
with DS. Longitudinal comparison of the CAMCOG and use of the IQCODE appear to enrich 
the analysis of cognitive decline in individuals with DS. Further studies involving larger samples 
are needed in order to corroborate and expand upon our findings, which can have implications 
for the clinical management of older adults with DS.
Keywords: cognitive decline, Down syndrome, bereavement, behavioral changes, Cambridge 
Cognitive Examination, Informant Questionnaire on Cognitive Decline in the Elderly 
Introduction
The genetic relationship between Down syndrome (DS) and the early development of 
neuropathological characteristics of Alzheimer’s disease (AD), attributed to overex-
pression of β-amyloid precursor protein on chromosome 21, is well documented.1–4 
Although dementia is considered the major problem faced by aging individuals with 
DS,5 there is a lack of data regarding the distinctions between cognitive decline related 
to the normal aging process and that characteristic of early indicators of neurodegen-
erative aspects of the syndrome.6,7 Although it is believed that, after reaching the age 
of 40 years, all individuals with DS have the neuropathological features of AD,4 it 
remains unclear why only some of them show early clinical evidence of the disease. 
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In addition, the precursors that hasten cognitive decline and 
trigger the clinical symptoms of AD in such individuals have 
yet to be identified. 
With the increase in life expectancy, individuals with 
DS are now more likely to experience the bereavement that 
follows the loss of a parent or caregiver. However, fam-
ily members and caregivers still underestimate the extent 
of the bereavement process in such individuals.8–10 There 
is considerable scientific evidence regarding the negative 
effects of stressful events on the physical and mental health 
of the population in general,11–13 regarding the association 
between depressive symptoms and a progressive decline 
in cognitive function14 and, more specifically, regarding 
bereavement as a risk factor for health problems in the 
elderly.15–17 It is also broadly hypothesized that intellectual 
disability (ID) is a predictor of mental health problems fol-
lowing bereavement.9,18–21 Nevertheless, there have been few 
prospective, population-based studies of this topic.22–24 In 
addition, we were unable to identify any studies using objec-
tive cognitive measures to determine the effects that bereave-
ment or other negative life events have on cognition in aging 
individuals with DS or other etiologies of ID. The recently 
developed concept of complicated grief (also referred to 
as prolonged grief disorder, traumatic grief, or persistent 
complex bereavement disorder) indicates the need for further 
investigations of the pathological grief response, in order 
to predict long-term functional impairments, especially in 
vulnerable populations.12,25–27 The DSM-V (Diagnostic and 
Statistical Manual of Mental Disorders, 5th Edition) includes 
persistent complex bereavement disorder in Conditions for 
Further Study,28 encouraging new research that would enable 
its inclusion with robust criteria in the next edition. The risk 
of persistent complex bereavement disorder is heightened by 
increased dependency on the deceased person.28 According 
to the ICD-10 (Tenth Revision of the International Clas-
sification of Diseases),29 symptoms of normal grief occur 
within 1 month of the death and do not persist for more than 
6 months. According to the DSM-V,28 normal grief does 
not persist for more than 12 months in adults and 6 months 
in children. The Diagnostic Manual-Intellectual Disability 
(DM-ID): A Textbook of Diagnosis of Mental Disorders in 
Persons with Intellectual Disability30 offers no adaptation for 
symptoms considered as part of normal grief in people with 
ID to those seen in the general population in the text revised 
edition of the Diagnostic and Statistical Manual of Mental 
Disorders, 4th Edition (DSM-IV).31,32 There is mounting 
evidence that the onset of grief is delayed and its duration 
is prolonged in individuals with ID.22,23,33
Many authors had pointed out that individuals with ID 
are vulnerable to development of pathological responses 
to the death of a loved one and negative life events, such 
responses including aberrant behavior and disease.9,18,19,21,24,33 
In a study investigating changes in health status, functional 
ability, and behavior among individuals with ID, parental 
death was associated with a behavioral change persisting for 
more than 2 years.23 There is also evidence that changes in the 
personality and behavior of adult individuals with DS often 
indicate prodromal (early stages of) AD,34–39 underscoring 
the importance of investigating the relationships between 
bereavement, behavioral changes, and cognitive decline. 
The instruments used for detection of cognitive decline 
and dementia in the general population are not well adapted 
for use in individuals with ID.30,40,41 AD remains one of the 
most commonly diagnosed and misdiagnosed mental disor-
ders in adults with DS.33 Screening instruments, such as the 
Mini-Mental State Examination (MMSE)42 and neuropsy-
chological assessment tests, identify signs of dementia by 
evaluating various cognitive functions but do not take into 
account pre-existing intellectual deficits, which can nega-
tively affect the performance of individuals on such tests. 
A recent systematic review showed that, although numerous 
instruments are used in order to screen for dementia in indi-
viduals with ID, the majority of them are not well adapted 
for use in this population.43 Some adapted instruments have 
recently been shown to produce consistent results in this 
population.35,40,41,44,45 However, in many countries, such 
instruments have yet to be validated, which makes it difficult 
to assess cognitive decline and to diagnose dementia. This 
also impedes the referral of patients for pharmacological and 
psychosocial treatment to mitigate or delay the consequences 
of progression of the disease. Given the difficulties in assess-
ing dementia and cognitive decline in such individuals, lon-
gitudinal comparison of individual performance has proven 
useful in their clinical evaluation.39,46–49 In heterogeneous 
populations, such as the population with ID, the use of a 
cognitive assessment instrument and a scale applied to the 
informant has proven to be more effective in detecting early 
and moderate cases of dementia, as well as cognitive decline, 
than is the use of a single instrument.50 Examples of such 
instruments include the Informant Questionnaire on Cogni-
tive Decline in the Elderly (IQCODE) and the Cambridge 
Cognitive Examination (CAMCOG).51,52
Our hypothesis was that a behavioral change associated 
with bereavement would increase the probability of cognitive 
decline in individuals with DS. Therefore, the objective of 
the present study was to investigate the correlations between Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
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cognitive decline, bereavement, and behavioral changes in 
adult individuals with DS not meeting the criteria for demen-
tia or depression. To that end, we applied the IQCODE and 
(for longitudinal comparison) the CAMCOG. 
Subjects and methods
subjects
All the subjects were enrolled in the Aging Support Service 
of the Association of Parents and Friends of Individuals 
with Intellectual Disability of São Paulo. The service has 
an interdisciplinary team approach and assists people with 
ID over the age of 35 years focusing on health and quality 
of life. Physical, corporal, and artistic activities are offered 
to enhance cognitive and functional abilities. In 2011, from 
among 49 individuals with DS over 35 years of age, all 
enrolled in that service and none meeting the criteria for 
dementia, we randomly selected 21 subjects. After base-
line evaluation, the selected subjects were followed for 
14–22 months (mean 18.33, standard deviation [SD] 3.06). 
The sample size of 21 and the differences in the length of 
follow-up were determined by limitations related to time 
constraints and lack of funding, the assessments being 
performed by one neuropsychologist from the institution 
who had other responsibilities within the facility, as well 
as to absences on the part of the subjects (for vacation and 
convalescence) or loss to follow-up. The diagnosis of DS 
was confirmed by cytogenetic analysis and by identification 
of phenotypic characteristics of DS. The level of ID was not 
analyzed, because none of the instruments designed to assess 
the degree of moderate and severe disabilities have yet been 
validated for use in Brazil. Therefore, in Brazil, the level of 
ID is determined by clinical evaluation, the results of which 
are often inconclusive or debatable. In the baseline evalua-
tion, a diagnosis of dementia, according to the ICD-10 and 
DSM-IV criteria, was one of the exclusion criteria. Of the 
21 selected subjects, two were suspected of having AD in the 
baseline evaluation, and that suspicion was confirmed during 
the follow-up period, and another subject was taking antide-
pressant medication during follow-up. Those three subjects 
were therefore excluded from the analyses, and the final 
sample was composed of 18 individuals. By follow-up, the 
sample was divided in two groups: six patients with DS who 
experienced bereavement, and 12 patients with DS who did 
not. For those who experienced bereavement, the mean length 
of follow-up was 18.5 (SD 3.09) months compared with 
18.16 (SD 3.03) months for the 12 remaining subjects.
The baseline assessments were performed at the facilities 
of the Aging Support Service of the Association of Parents 
and Friends of Individuals with Intellectual Disability of São 
Paulo. During the follow-up period, the majority of subjects 
and informants were evaluated at the same institution, except 
for three who were no longer enrolled in the program and 
were assessed in their homes.
The study was approved by the research ethics committee 
of the Federal University of São Paulo. All subjects and their 
legal guardians gave their written informed consent. 
Demographic data
Of the 18 subjects, 12 were male and six were female. All 
were living in private residences with family members, 
except for one who was living alone with family supervi-
sion. The age at baseline ranged from 35 to 55 years (mean 
42.44, SD 6.11). Fourteen of the subjects were illiterate. One 
subject had never attended school. The remaining subjects 
had studied in schools specialized in educating individuals 
with ID, although one subject had attended regular school 
up to the fourth grade.
health status
The diagnosis of dementia or depression was made by a 
geriatrician through clinical analysis based on the criteria 
established in the ICD-10 and the DSM-IV.29,32 The attending 
physician was blinded to the results of the neuropsychological 
assessments and the cognition scores. None of the subjects 
met the criteria for a diagnosis of depression. Eight of the 
subjects had comorbidities: hypothyroidism, in eight; heart 
disease, in two; pulmonary hypertension, in one; digestive 
disorder, in one; coagulation disorder, in one; gout, in one; 
and high cholesterol, in one. Four subjects had only one 
comorbidity, whereas two had two, one had three, and one 
had four comorbidities. All cases with hypothyroidism were 
effectively treated at baseline and follow-up.
Of the 18 subjects, eight were using some type of medica-
tion. Of those eight, one was taking a neuroleptic, a medica-
tion that affects the central nervous system. The latter subject 
had not been recently bereaved.
longitudinal neuropsychological 
evaluation
caMcOg
The CAMCOG is a brief neuropsychological battery that is 
part of the Cambridge Examination for Mental Disorders of 
the Elderly interview.52 The CAMCOG offers a wide pos-
sibility of scores, covering several cognitive functions, as 
well as incorporating the MMSE. The test has subscales for Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
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orientation, language, memory, attention, praxis, calculation, 
abstract thinking, and perception.
The CAMCOG has been applied in the general popula-
tion, and it has been shown that there are significant differ-
ences between the population without dementia and that 
of those with early-stage or intermediate-stage dementia, 
in terms of the total CAMCOG score and each of the sub-
scale scores.53 The CAMCOG has been validated for use 
in Brazil.54,55 The CAMCOG longitudinal comparison has 
been investigated by various researchers, who achieved good 
results for evaluation of normal and pathological declines in 
the general population.56–58 Researchers in England adapted 
the CAMCOG for use in individuals with ID,35 and a recent 
study involving the application of the CAMCOG for DS 
validated it for use in the ID population of Spain.44
In the present study, longitudinal comparison of neu-
ropsychological performance involved application of the 
CAMCOG at baseline and after 14–22 months of follow-up. 
The CAMCOG was administered by a professional properly 
trained in the use of the instrument and blinded to any pre-
vious results. As comparison data for measuring cognitive 
decline, we employed the results of CAMCOG longitudinal 
comparisons obtained in studies of populations without DS, 
including those conducted by Cullum et al57 who reported 
an annual decline of 1.6 points per year; Brayne et al56 who 
observed a normal decline of 4.7 points in 5 years; and 
Jonker et al58 who reported an annual decline of 1.4 points 
for carriers of the apoE4 allele and 0.4 points for noncar-
riers. Although we recognize the fact that there are major 
differences among the studies, in terms of subject ages and 
sample sizes, we considered it important to cite these studies, 
because we were unable to identify any reference values for 
normal cognitive decline in aging individuals with DS. The 
cognitive decline observed in our study sample was quantified 
and correlated with the other variables evaluated. 
iQcODe
The IQCODE is a widely used instrument that is easily 
applied to heterogeneous, uneducated populations,51,58,60 as 
well as being an instrument that is applied to the informant. 
The IQCODE is a rating scale of cognitive and functional 
decline that compares the current performance of the subject 
with that of 10 years ago. By making this comparison over 
time, the instrument does not take into account a standard of 
behavior, but rather the standard of functionality achieved by 
each individual during adulthood. Therefore, the IQCODE 
is easily adapted for use in individuals with different levels 
of education or disability. The IQCODE consists of 26 items 
that are simple and easy to understand. It has been validated 
for use in Brazil, where it has been shown to be sensitive and 
specific in screening for dementia in the elderly.60,61
We found no studies using the IQCODE specifically 
for individuals with DS, although the 16-item short form 
IQCODE59 was used in one study evaluating individuals with 
ID.62 The authors concluded that the short form IQCODE 
probably needs to be modified for use in this population, 
although they acknowledged that some study limitations 
might have resulted in suboptimal estimates and made their 
findings questionable. As the authors pointed out, there are 
many important methodological limitations, such as limited 
contact between the informant and subject and variations in 
the time frame of caregiver–subject contact (2–10 years), 
that is not in accordance with the procedures outlined for 
the IQCODE, which state that the informant (the primary 
caregiver) must have had daily contact with the subject for 
at least 10 years. In our study, we aimed to avoid the same 
missteps. Certain social and cultural aspects of our sample 
allow us to hypothesize that the IQCODE could be a suit-
able tool for use in our population, because individuals with 
DS in Brazil often live with their families, rather than being 
institutionalized. 
In the present study, the IQCODE was administered by 
a trained professional. All informants who completed the 
questionnaire had daily contact with the subject, relation-
ships established at least 10 years prior, and were the primary 
caregivers at the time of evaluation. To categorize the degree 
of decline, as investigated by the IQCODE, we used a total 
IQCODE score 3 (any cognitive decline) and the cut-off 
scores for dementia of 3.16 reported for the Brazilian 
population by Perroco et al.60 
Medication use and comorbidities 
The study protocol involved collecting data related to the use 
of medications at baseline and during follow-up and identify-
ing comorbidities, especially hypothyroidism. 
Behavioral changes
During the follow-up period, reports of behavioral changes 
in the last 2 years, as measured by the Neuropsychiatric 
Inventory,63,64 were collected from the staff of the institu-
tion and from family members. In our analysis, behavioral 
changes were defined as any type of behavioral change 
identified by the Neuropsychiatric Inventory (delusions, 
hallucinations, dysphoria, anxiety, agitation/aggression, 
euphoria, disinhibition, irritability/lability, apathy, or aber-
rant motor activity). Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
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Bereavement
We collected information regarding the deaths of primary 
caregivers during the 2 years prior to follow-up. All of our 
assessments were made at least 6 months after those deaths. 
The length of time between bereavement and the follow-up 
assessment tests for each patient was 24, 18, 12, 6, 12, and 
24 months (n=6, mean 16, SD 6.63). The information was 
obtained from the individual who was the primary caregiver 
at the time of evaluation. 
statistical analysis
Assumptions of homogeneity between groups of demo-
graphic features were verified with the Chi-square test. 
We observed a heterogeneous sex distribution only for the 
variables ΔCAMCOG score and IQCODE cut-off score 
of 3.16. Therefore, for those variables, we used backward 
stepwise logistic regression adjusted for sex to determine the 
relevance of the other variables, calculating odds ratios and 
estimated probabilities. 
To identify differences between the baseline and final 
evaluations, in terms of the CAMCOG subscale scores, we 
used the nonparametric Wilcoxon test.
We constructed receiver operating characteristic curves 
(ROC curves) in order to determine the relevance of the 
IQCODE score in relation to the degree of cognitive decline 
determined with the CAMCOG. For the equivalence of mean 
difference in CAMCOG with other studies, we used one-
sample t-tests and confidence intervals. 
All selected data were analyzed using Statistical Package 
for the Social Sciences version 14.0 software for Windows 
(SPSS Inc., Chicago, IL, USA). The level of statistical sig-
nificance was set at 5%.
Results
Measures of cognitive decline
caMcOg scores
Of the 18 subjects included in the study,  eleven showed 
some degree of cognitive decline during the 14–22 months 
of follow-up, as evidenced by the difference between the 
baseline and final evaluations, in terms of the ΔCAMCOG 
score (mean −4.63, SD 3.17). Of the seven subjects who 
showed no cognitive decline, six actually showed some 
improvement in cognitive function and one remained the 
same (mean ΔCAMCOG score for the subgroup 2.57, SD 
1.98). The mean ΔCAMCOG score for the sample as a whole 
was −1.83 points (SD 4.51, 95% confidence interval [CI] 
−4.07 to 0.41). This value is comparable with the −1.88 (95% 
CI −2.36 to −1.36, P=0.966), −2.7 (95% CI −3.58 to 1.82, 
P=0.427), and −3.2 (95% CI −4.0 to −2.2, P=0.216) reported 
for the general elderly population in a linear estimation of 
2 years by Brayne et al,56 Jonker et al,58 and Cullum et al,57 
respectively.
The areas of greatest cognitive decline on the CAMCOG 
scale, as measured by the Wilcoxon test, were the domains 
of language (P=0.025), abstract thinking (P=0.046), and 
perception (P=0.034). Of the 18 subjects, eleven (61%) 
exhibited some decline in the language domain, mainly in 
comprehension (P=0.020). 
iQcODe scores
Eleven of the 18 informants had observed a functional decline 
in some area, as measured by the IQCODE, within the last 
10 years. In our box-plot analysis of the mean IQCODE 
scores, we identified three outliers indicating a functional 
gain (IQCODE score 2). When those three outliers were 
excluded, the mean IQCODE score was 3.12 (n=16, 95% 
CI 3.02–3.22). 
caMcOg versus iQcODe
The receiver operating characteristic curve in which the 
dependent variable was CAMCOG-determined cogni-
tive decline showed that the IQCODE discriminates 
well between groups (ROC curve area 0.734, 95% CI 
0.498–0.970).
Responses indicative of worsening on the IQCODE 
items related to memory (items 1–10, 15, 16, and 21) and 
were found to correlate significantly with a decline in the 
CAMCOG memory subscale score (P=0.013).
The IQCODE items that had the highest rates of “not 
applicable” responses were items 24 (mean 0.83, 95% CI 
0.64–1.02), 23 (mean 0.72, 95% CI 0.49–0.95), 20 (mean 
0.61, 95% CI 0.36–0.86), and 21 (mean 0.56, 95% CI 0.30–
0.81). Table 1 shows which IQCODE items had the great-
est influence on the decline in the total IQCODE score, the 
distribution of responses by item, and the relative risk of 
positive response in each item, stratified by the IQCODE 
score (3.16).
Behavioral changes, bereavement, 
and cognitive change
None of our 18 subjects exhibited delusions, hallucinations, 
or aberrant motor activity. A total of eleven subjects exhibited 
at least one behavioral change, six exhibited only one, four 
exhibited two, and one exhibited four. Three of the subjects 
exhibited agitation/aggression, one exhibited euphoria, 
one exhibited anxiety, two exhibited apathy, two exhibited Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
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dysphoria, four exhibited disinhibition, and five exhibited 
irritability/lability. Six subjects lost their primary caregiver 
during the study period, and all of them exhibited behavioral 
changes after the loss. 
We found that behavioral changes had a direct influence 
on cognitive decline (P=0.049). For the eleven subjects 
who exhibited behavioral changes, the mean ΔCAMCOG 
score was −3.81 (SD 3.78), compared with 1.28 (SD 3.90) 
for the seven remaining subjects (P=0.035), indicating that 
the subjects exhibiting no behavioral changes also showed 
no cognitive decline. 
Six subjects had recently gone through a period of 
bereavement after the death of their primary caregiver, 
and all of those subjects exhibited subsequent behavioral 
changes, compared with only half of the subjects who had not 
recently been bereaved. Five of those six subjects (83%) also 
showed a decline in their CAMCOG score. For those who 
experienced bereavement, the mean ΔCAMCOG was −4.16 
(SD 4.41, 95% CI −8.43, −0.10), compared with −0.66   
(SD 4.07, 95% CI −3.47, 2.14) for the 12 remaining subjects 
(comparison not considered statistically significant). Figure 1 
shows the differences in the subscale scores after follow-up 
between the two groups, and Table 2 describes the differences 
including demographic characteristics, length of follow-up 
time, CAMCOG total score, and subscale scores, as well as 
behavioral changes. 
Using the Kolmogorov–Smirnov test, we found that the 
IQCODE data did not follow a normal distribution. There-
fore, to assess the relevance of the variables to the IQCODE 
score, we stratified the results into two categories: worse 
performance (IQCODE score 3) and the same or better 
performance (IQCODE score 3). Using logistic regression 
in which the dependent variable was an IQCODE score 3, 
the independent variables being behavioral change and 
Table 1 informant Questionnaire on cognitive Decline in the elderly items and its relationship to cognitive decline
IQCODE item Combined frequency  
of response  
(worsened)
Chi-square for IQCODE score 3.16 
% of positive 
responses
Relative risk P-value
3.16 3.16
  4. remembering things that have happened recently  22.2% 7.1% 75% 10.5 0.019
  6.   Forgetting what he/she wanted to say in the middle of  
a conversation
27.8% 14.3% 75% 5.2 0.044
11. adjusting to any change in his/her day-to-day routine 27.8% 14.3% 75% 5.2 0.044
14. learning new things in general 27.8% 14.3% 75% 5.2 0.044
22. Making decisions on everyday matters 33.3% 14.3% 100% 6.9 0.005
Note: We have listed only the IQCODE items for which there was a statistically significant correlation with cognitive decline.
Abbreviation: iQcODe, informant Questionnaire on cognitive Decline in the elderly.
Figure 1 Differences in subscale scores and total score on the caMcOg, as well as the MMse score, between bereaved and not bereaved groups after 2 years of follow-up 
in 18 individuals with Down syndrome.
Notes: Data shown are mean ± standard deviation. area of greatest difference on cognition by Wilcoxon test.
Abbreviations: caMcOg, cambridge cognitive examination; MMse, Mini-Mental state examination; n, number of subjects.
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Table 2 Differences between groups: bereaved and not bereaved
Not bereaved (n=12) Bereaved (n=6) Differences between groups
Mean SD Mean SD P-value (by Mann–Whitney test)
age at baseline, years 43.75 6.76 39.83 3.82 0.397
age at follow-up, years 44.83 6.78 41.33 4.03 0.452
Follow-up period (months) 18.33 3.06 18.33 3.39 0.850
Baseline scores
Orientation 7.33 2.10 7.17 1.84 0.811
language total 16.00 4.13 16.33 3.93 0.887
comprehension 4.42 1.62 4.17 0.98 0.885
expression 11.58 2.81 12.33 2.81 0.887
Memory total 11.50 4.36 12.67 5.13 0.573
long-term memory 1.08 0.79 1.33 0.82 0.514
short-term memory 2.50 1.17 1.50 0.84 0.078
learning 7.92 3.68 10.00 4.34 0.202
attention 0.17 0.58 0.00 0.00 0.480
Praxis 7.92 1.38 8.00 1.10 0.810
calculation 0.17 0.39 0.17 0.41 1.000
abstract thought 2.25 1.36 2.67 2.66 0.809
Perception 7.25 1.14 8.00 1.55 0.337
caMcOg total 52.58 11.63 54.17 11.62 0.850
MMse 15.17 3.86 13.67 4.41 0.451
Follow-up scores
Follow-up period (months) 18.33 3.06 18.33 3.39 0.850
Orientation 7.00 2.00 5.83 3.37 0.538
language total 14.92 3.32 14.50 4.14 0.814
comprehension 3.50 1.24 3.00 1.79 0.382
expression 11.42 2.61 11.67 2.66 0.962
Memory total 12.17 4.69 10.83 6.08 0.572
long-term memory 1.08 0.79 1.17 0.98 0.955
short-term memory 2.92 1.00 1.50 1.38 0.034
learning 8.58 3.63 8.17 4.75 0.963
attention 0.08 0.29 0.00 0.00 0.480
Praxis 8.08 1.00 8.33 0.82 0.652
calculation 0.17 0.39 0.00 0.00 0.303
abstract thought 1.83 1.75 1.17 1.33 0.408
Perception 7.58 1.51 9.17 1.47 0.054
caMcOg total 51.92 11.87 50.00 14.31 0.639
MMse 14.83 4.24 13.67 4.93 0.638
iQcODe  3.05 (n=9)† 0.11 (n=9)† 3.23 0.22 0.027
n % n % P-value (by Fisher’s exact test)
sex (male) 7 58.3 5 83.3 0.600
literacy (illiterate) 8 66.7 6 100.0 0.245
comorbidity (without) 6 50.0 4 66.7 0.638
iQcODe 3.16 1 8.3 3 50.0 0.083
any change in behavior  5 41.7 6 100.0 0.038
Kind of behavior change
agitation/aggression 1 8.3 2 33.3 0.245
euphoria 0 0 1 16.7 0.333
anxiety 0 0 1 16.7 0.333
apathy 0 0 2 33.3 0.098
Dysphoria 0 0 2 33.3 0.098
Disinhibition 3 25.0 1 16.7 1
irritability/lability 3 25.0 2 33.3 1
Note: †Excluded three outliers (identified by box-plot analysis).
Abbreviations: MMse, Mini-Mental state examination; caMcOg, cambridge cognitive examination; iQcODe, informant Questionnaire on cognitive Decline in the 
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bereavement, we found that behavioral changes worsened 
IQCODE performance. When there was a behavioral change, 
the probability of a cognitive decline, as measured by the 
IQCODE, was 48% in the absence of bereavement (odds 
ratio 16.00, 95% CI 1.13–12.93, P=0.030) compared with 
87% in the presence of bereavement (odds ratio 3.82, 95% 
CI 1.31–194.62, P=0.031). 
additional variables
Age and the MMSE score showed no statistically significant 
correlation with the CAMCOG scores or with a worsening of 
the IQCODE score. Cognitive change, whether determined 
by IQCODE, CAMCOG, or MMSE, was not found to cor-
relate significantly with the length of the follow-up period, 
literacy, sex, medication use, or comorbid hypothyroidism.
Discussion
The major finding of this study is that behavioral changes 
associated with death of the primary caregiver significantly 
increased the probability of cognitive decline in adult indi-
viduals with DS. Our results suggest that clinicians should 
take behavior and bereavement into consideration when 
dealing with aging individuals with DS. Because of the small 
size of our study sample, this finding should be interpreted 
with caution. Further studies are needed in order to cor-
roborate our results, warranting replication and representing 
encouragement on future investigation of the intersection of 
DS with aging and thanatology, a small but growing field in 
terms of the interest shown by researchers.65 In addition, the 
investigation of bereavement in individuals with DS or other 
forms of ID could also aggregate knowledge to further the 
understanding of persistent complex bereavement disorder, 
as proposed in the DSM-V.28
Another important finding of the present study is that 
behavioral change was identified as a major variable in 
relation to occurrence of cognitive decline as measured by 
CAMCOG and IQCODE. On the basis of this finding and 
the observation that a lack of behavioral change appeared to 
correspond with a lack of cognitive decline, we believe that, 
in individuals with DS, behavioral changes precede or occur 
concomitantly with cognitive decline, in agreement with 
the results of other cross-sectional and longitudinal studies 
involving larger samples.13,35–39 Nevertheless, DM-ID30 calls 
attention to the fact that there is need for more research to 
better define which behaviors are related to cognitive decline 
and dementia. Cognitive change measured by IQCODE 
was significantly different between the bereaved and not 
bereaved groups, indicating a greater decline for those who 
were bereaved. Although the difference in CAMCOG was 
not significantly different between the groups, it is possible to 
observe that the range interval for those who were bereaved is 
always negative, while for the remaining subjects the interval 
is centered at zero, suggesting that results with larger samples 
could reach significance. 
Due to their ID, our subjects performed poorly on some 
of the CAMCOG subscales in the initial and final evalua-
tions, which confirms the appropriateness of adaptation of the 
instrument to the specifics of the population of individuals 
with ID.35 Similarly, we observed that there was a high rate 
of “does not apply” responses to the IQCODE items related 
to handling money and dealing with finances (items 23 and 
24), which had no impact on the total IQCODE score, but 
suggests that the instrument should be modified for use in 
this population. Although longitudinal analyses using tools 
adapted to this population might be more sensitive to detailed 
analysis of cognition of adults with DS, we can conclude that 
the use of the CAMCOG and the IQCODE would be useful 
to complement assessment of cognitive decline and assist in 
the diagnosis of dementia. 
The fact that none of our subjects were diagnosed with 
depression (as defined in the ICD-10 and DSM-IV), together 
with the evidence that cognitive decline is associated with 
bereavement and behavioral changes, raises the question of 
whether the diagnostic criteria for depression are appropriate 
and sufficient for use in this population, since assessment of 
mood is considered a challenge when dealing with patients 
with ID.30,33 
The main limitations of our study were its small sample 
size and failure to assess the degree of ID prior to inclu-
sion of the subjects. In addition, the lack of instruments 
adapted for use in the target population can be considered 
a limitation, as can the lack of validated quantitative instru-
ments to examine in detail the experience of bereavement 
in the subjects themselves, rather than solely on the basis 
of information obtained from the primary caregiver. It is 
also important to consider that although we were careful 
about length of time between bereavement and assess-
ment according to ICD-10 and DSM-IV criteria, there is 
no consensus about the length of time needed to capture 
changes after bereavement in people with ID. Some authors 
point to the possibility that the normal bereavement period 
could be extended22 and its consequences can often appear 
after years of loss through other triggers.33 Because of this, 
future research with constant follow-up could allow a better 
understanding of the duration of grief and its expression in 
cognition.Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
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Considering the complexity of the theme investigated, 
we can state that our study raised many questions that merit 
further investigation. Should individuals with ID be con-
sidered at risk for developing persistent complex bereave-
ment disorder? Can the cognitive decline associated with 
bereavement be considered a reversible feature caused by 
reactive depression in individuals with DS? Does the use 
of the current diagnostic criteria result in depression being 
underdiagnosed in individuals with DS? Is it possible to 
distinguish the effects of grief from those of dealing with 
structural changes following the death of a primary care-
giver? Is bereavement truly a risk factor for dementia in 
aging individuals with DS? 
Future longitudinal cognitive studies in larger samples 
could be useful in estimating the average expected cognitive 
decline in individuals with DS at various ages, in comparison 
with the general population, establishing criteria for differ-
entiating between normal and pathological processes, and 
broadening our understanding of the mild cognitive impair-
ment concept for this population. 
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